9 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 9 Phase 1, 8 Phase 2.
By phase and status
Follow Sirnaomics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
STP705 Injection for Submental Fat Reduction STP705 - Submental Fullness | Phase 2 | Recruiting | 30 | 2026-07-28 | 2026-08-10 |
Single Ascending Dose of FXI-GalNAc-siRNA in Healthy Subjects FXI-GalNAc-siRNA, Placebo - FXI | Phase 1 | Active not recruiting | 40 | 2023-05-16 | 2026-07-29 |
A Study to Evaluate Safety, Tolerability of Subcutaneous Injection in Adult Subjects Undergoing Abdominoplasty STP705 - Abdominal Obesity | Phase 1 | Completed | 8 | 2022-08-01 | 2024-03-18 |
Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Adults With Facial isSCC STP705 - Facial isSCC | Phase 1 / Phase 2 | Terminated | 9 | 2022-08-01 | 2026-10-07 |
A Study of STP707 Administered by IV in Healthy Subjects STP707 - Healthy Subjects | Phase 1 | Completed | 20 | 2022-02-28 | 2024-03-18 |
Safety, Tolerability, Pharmacokinetics, Immunogenicity and Efficacy of STP705 in Adult Patients With Hypertrophic Scars STP705 - Hypertrophic Scar | Phase 1 / Phase 2 | Withdrawn | | 2021-12-07 | 2026-07-29 |
Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors STP707 - Solid Tumor | Phase 1 | Completed | 50 | 2021-11-01 | 2026-07-29 |
A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC STP705, Placebo Saline - Squamous Cell Carcinoma in Situ | Phase 2 | Completed | 44 | 2021-05-18 | 2024-03-18 |
A Study for Safety and Efficacy Evaluation of Various Doses of STP705 in Reducing Keloid Recurrence STP705, Placebo - Keloid | Phase 2 | Completed | 29 | 2021-04-29 | 2024-03-19 |
Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy STP705 - Hepatocellular Carcinoma, Liver Metastases | Phase 1 | Completed | 5 | 2021-03-01 | 2024-03-19 |
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma STP705 - Basal Cell Carcinoma | Phase 2 | Completed | 32 | 2020-12-28 | 2026-09-24 |
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC STP705 - Bowen's Disease, Cutaneous Squamous Cell Carcinoma in Situ | Phase 1 / Phase 2 | Completed | 25 | 2019-03-21 | 2022-06-09 |
A Randomized Study to Evaluate the Safety and Efficacy of Various Doses of STP705 in Subjects With Hypertrophic Scar STP705, Placebo - Hypertrophic Scar | Phase 1 / Phase 2 | Completed | 25 | 2017-01-01 | 2021-11-24 |
Conditions studied
Cicatrix, Hypertrophic (2) · Bowen's Disease (1) · Carcinoma, Basal Cell (1) · Carcinoma, Hepatocellular (1) · Cholangiocarcinoma (1) · Keloid (1) · Obesity, Abdominal (1) · Squamous Intraepithelial Lesions (1)
Interventions
Injections (8)
Countries
United States (11) · Australia (1) · Canada (1) · China (1)
Top investigators
Mark Nestor, MD (4) · Francois Lebel, MD (3) · Brenda LaTowsky, MD (2) · Andrae Vandross, MD (1) · Angela Alistar, MD (1) · Anthony El-Khoueiry, MD (1) · Brian Berman, MD, PhD (1) · Brian Jiang, MD (1) · Christina Wu, MD (1) · Conor Steuer, MD (1) · David Goldberg (1) · David Goldberg, MD (1) · Edward Lain, MD (1) · Edward Primka, MD (1) · Girish Munavalli, MD (1)
Results publications
PMID 32889812, PMID 39692702